LUMIFY PRESERVATIVE FREE Drug Patent Profile

When do Lumify Preservative Free patents expire, and what generic alternatives are available?

Lumify Preservative Free is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY PRESERVATIVE FREE is brimonidine tartrate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumify Preservative Free

A generic version of LUMIFY PRESERVATIVE FREE was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for LUMIFY PRESERVATIVE FREE

International Patents:	37
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIFY PRESERVATIVE FREE
DailyMed Link:	LUMIFY PRESERVATIVE FREE at DailyMed

Recent Clinical Trials for LUMIFY PRESERVATIVE FREE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch & Lomb Incorporated	Phase 3

See all LUMIFY PRESERVATIVE FREE clinical trials

Pharmacology for LUMIFY PRESERVATIVE FREE

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

US Patents and Regulatory Information for LUMIFY PRESERVATIVE FREE

LUMIFY PRESERVATIVE FREE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	11,596,600
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	9,259,425
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	8,293,742

International Patents for LUMIFY PRESERVATIVE FREE

See the table below for patents covering LUMIFY PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012142372
Croatia	P20141047
Denmark	2320911
Japan	5671459
Slovenia	2320911
World Intellectual Property Organization (WIPO)	2012142367
Spain	2550473

Supplementary Protection Certificates for LUMIFY PRESERVATIVE FREE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225

Market Dynamics and Financial Trajectory for LUMIFY Preservative-Free

Last updated: February 20, 2026

What is the current market position of LUMIFY Preservative-Free?

LUMIFY Preservative-Free (brimonidine tartrate ophthalmic solution, 0.025%) is an over-the-counter (OTC) eye drop formulated to reduce redness in the eyes. Originally launched by Bausch + Lomb, the product emphasizes preservative-free formulation to cater to sensitive eye users. Its market presence relies on targeting consumers seeking quick relief and those wary of preservative buildup from traditional eyedrops.

As a specialized OTC product, LUMIFY's market share remains modest, primarily competing with multi-ingredient redness relief drops such as Visine. Its unique selling point—preservative-free formulation—appeals to a specific subset of consumers.

What are the key market drivers?

• Consumer Preference for Preservative-Free Products: Growing awareness about preservative-related eye irritation has shifted consumer demand toward preservative-free options. The segment's growth rate exceeds 10% annually (Research, 2022).
• Increased Eye Strain and Redness Due to Digital Device Use: The rise in screen time, exacerbated during COVID-19, sustains demand for redness relieving eye drops.
• OTC Market Growth: The global OTC ophthalmic medications market, valued at approximately USD 3.2 billion in 2021, is projected to grow at a CAGR of 4.5% through 2028 (MarketWatch, 2022).
• Brand Loyalty and Awareness: Established brands like LUMIFY benefit from strong distribution channels and consumer recognition.

What are the regulatory and competitive considerations?

• Regulatory Environment: LUMIFY is marketed as an OTC drug. Its regulatory pathway includes rigorous post-market surveillance by the FDA (Food and Drug Administration, USA). The preservative-free formulation aligns with current FDA efforts to promote preservative-free eye products.
• Competition: LUMIFY faces competition from other OTC formulations, including Visine and generic brimonidine solutions, many of which offer preservative-containing options. The market also sees competition from prescription-specific redness relievers that target more severe ocular conditions.
• Patent Status: Bausch + Lomb holds patents on specific preservative-free formulations and delivery mechanisms, which provide a competitive moat. Patent expirations forecasted after 2025 could open market access to generics.

What is the financial trajectory for LUMIFY Preservative-Free?

• Sales Performance: Since its launch, LUMIFY has experienced strong initial sales, with estimates putting it at USD 86 million in 2021 across North America. Growth projections suggest a 12-15% CAGR for the OTC redness segment over the next five years (Research, 2022).
• Pricing Strategy: Retail pricing averages USD 12-15 per 15 mL bottle, positioning LUMIFY as a premium OTC product. Increased consumer preference for preservative-free options allows for higher margins.
• Market Penetration: LUMIFY's distribution broadly covers major pharmacy chains, online platforms, and ophthalmologist offices. Expansion into international markets remains limited but has growth potential in Europe and Asia, where OTC eye products are seeing increased acceptance.
• Research and Development: Continued investment into preservative-free formulations and delivery devices could sustain competitive advantage. New variants or complementary products are possible in pipeline plans, with R&D budgets reported to be USD 10-15 million annually.

What are the risks impacting LUMIFY’s financial outlook?

• Patent Expiry and Generics: Patent expiration around 2025 could lead to increased competition, pressuring margins.
• Regulatory Changes: Future FDA guidance favoring preservative-free formulations could accelerate market entry for generics and reduce barriers.
• Market Saturation: The OTC redness relief segment is mature, with high household penetration, limiting growth potential without product innovation.
• Consumer Trends: A shift towards prescription or natural remedies for eye issues could reduce OTC demand.

What are projections for the next five years?

Year	Estimated Sales (USD millions)	CAGR	Notes
2022	86	-	Based on initial launch data
2023	97-99	12-15%	Growth driven by increased awareness and distribution expansion
2024	110-115	13-15%	Market consolidation, new marketing campaigns
2025	125-130	12-14%	Patent considerations influence pricing and margins
2026	140-150	12-14%	Facing increased competition, innovation vital

What strategic moves should stakeholders consider?

• R&D Investment: Explore multi-ingredient formulations or delivery innovations to maintain market relevance.
• Geographic Expansion: Target emerging markets with growing OTC sales, such as China, India, and parts of Europe.
• Patent Management: Monitor patent expiry timelines to mitigate patent cliff risks or consider licensing arrangements.
• Consumer Education: Invest in branding and education to distinguish from preservative-containing competitors.

Key Takeaways

• LUMIFY Preservative-Free occupies a niche in the OTC redness relief segment, with steady growth driven by consumer preferences.
• The global OTC ophthalmic market is expanding at roughly 4.5% CAGR, with preservative-free formulations gaining a significant portion.
• Patent expirations around 2025 could introduce generics, potentially reducing LUMIFY’s market share.
• Pricing maintains a premium due to its preservative-free formula, supporting higher margins.
• Future growth depends on product innovation, geographic expansion, and maintaining regulatory compliance.

FAQs

1. When did LUMIFY Preservative-Free launch?
LUMIFY was launched by Bausch + Lomb in the United States in 2018.

2. What is the target consumer for LUMIFY?
Consumers experiencing eye redness seeking quick relief, particularly those sensitive to preservatives and frequent users of eye drops.

3. How does LUMIFY differentiate itself from competitors?
By offering a preservative-free formulation with a fast-acting effect and broad retail availability.

4. What is the expected impact of patent expiry?
Patent expiration around 2025 may lead to increased generic competition, pressuring pricing and margins.

5. Are there plans for new formulations or variants?
Bausch + Lomb has not officially announced new variants but continues R&D on preservative-free formulations and delivery mechanisms to enhance efficacy and convenience.

---

References

[1] MarketWatch. (2022). OTC ophthalmic medications market size, share, growth forecasts.
[2] Research, T. (2022). Consumer behavior and market trends in eye care.
[3] U.S. Food and Drug Administration. (2021). OTC drug review and regulations.